Dr. Schooley began his research career studying the immunopathogenesis of herpesvirus infections in immunocompromised patients, but shifted his focus to AIDS in 1981 when the first cases of this syndrome began to appear in Boston. His research group was among the first to delineate the humoral and cellular immune responses to HIV infection. Over the next 15 years, he became increasingly involved in the discovery and development of antiretroviral chemotherapeutic agents including reverse transcriptase inhibitors, protease inhibitors and entry inhibitors. He was recruited to the University of Colorado Health Sciences Center in 1990 to serve as head of the Division of Infectious Diseases. While at Colorado, he was elected to serve as chair of the NIAID’s AIDS Clinical Trials Group (ACTG), which he headed from 1995 – 2002. During his tenure as group chair, the ACTG expanded to include research sites in Latin America, the Caribbean, South Asia and Africa and is now the largest and most productive multinational clinical and translational research organization focusing on the pathogenesis and therapy of HIV and its complications. Currently, Dr. Schooley's personal research interests include HCV, influenza and HIV pathogenesis, and therapy and infections that cause morbidity and mortality in resource limited settings.
He has extensive experience in conducting clinical and translational research and developing research capacity in resource limited settings, including sub- Saharan Africa and Latin America. He is also one of the global leaders in the development of bacteriophages for the treatment of multidrug bacterial infections.
Areas of Expertise (8)
John Hopkins University of Medicine: M.D., Medicine 1972
Washington and Lee University: B.S., Chemistry
Media Appearances (3)
Phage Therapy Offers Lifeline for Antimicrobial Resistance
Strathdee, Associate Dean of Global Health Sciences and an expert on the health of people who use drugs, her husband, Thomas Patterson, PhD, a professor of psychiatry known for his HIV prevention work, and Robert "Chip" Schooley, MD, a renowned HIV expert and professor of medicine, all at UCSD, spoke at the closing plenary of IDWeek, jointly sponsored by the Infectious Diseases Society of America (IDSA), the HIV Medicine Association (HIVMA), the Society for Healthcare Epidemiology of America (SHEA), and the Pediatric Infectious Diseases Society (PIDS)...
Phage therapy draws renewed interest to combat drug-resistant microbes
She was so inspired by the team's ingenuity that DeBiasi, program vice-chair, invited them to recount the story during IDWeek2018, held Oct. 3 to Oct. 7, 2018, in San Francisco. During the closing plenary, Patterson, a professor of psychiatry, and Strathdee, associate dean of Global Health Sciences, will be joined by Robert T. "Chip" Schooley, M.D., (all of University of California, San Diego), to discuss the clinical aspects and efficacy of phage therapy...
Dr. Chip Schooley on infectious diseases & journal publishing
As infectious diseases around the world continue to evolve, so does the research surrounding the discipline. To find out more about the progress and future challenges in this field, we’ve caught up with Robert T. “Chip” Schooley, editor-in-chief of the journal Clinical Infectious Diseases (CID), who began his term in January after serving as an associate editor for the past decade. We recently asked Dr. Schooley about the role he sees the journal playing as the field of infectious diseases continues to change and grow...